TY - JOUR AU - Schreiber, R. D. AU - Old, L. J. AU - Smyth, M. J. PY - 2011 DA - 2011// TI - Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion JO - Science VL - 331 UR - https://doi.org/10.1126/science.1203486 DO - 10.1126/science.1203486 ID - Schreiber2011 ER - TY - JOUR AU - Hanahan, D. AU - Weinberg, R. A. PY - 2011 DA - 2011// TI - Hallmarks of cancer: the next generation JO - Cell VL - 144 UR - https://doi.org/10.1016/j.cell.2011.02.013 DO - 10.1016/j.cell.2011.02.013 ID - Hanahan2011 ER - TY - JOUR AU - Kim, H. -. J. AU - Cantor, H. PY - 2014 DA - 2014// TI - The path to reactivation of antitumor immunity and checkpoint immunotherapy JO - Cancer Immunol Res VL - 2 UR - https://doi.org/10.1158/2326-6066.CIR-14-0153 DO - 10.1158/2326-6066.CIR-14-0153 ID - Kim2014 ER - TY - STD TI - Zou W, Chen l. Inhibitory B7-family molecules in the tumour microenvironment. Nat Review Immune 2008;8:467-477. ID - ref4 ER - TY - JOUR AU - Jantzer, P. AU - Schendel, D. J. PY - 1998 DA - 1998// TI - Human renal carcinoma antigen-specific CTLs, antigen-driven selection and long-term persistence in vivo JO - Cancer Res VL - 58 ID - Jantzer1998 ER - TY - JOUR AU - Bromwich, E. J. AU - McArdle, P. A. AU - Canna, K. AU - McMillan, D. C. AU - McNicol, A. M. AU - Brown, M. AU - Aitchison, M. PY - 2003 DA - 2003// TI - The relationship between T-lymphocyte infiltration, stage, tumour grade and survival in patients undergoing curative surgery for renal cell cancer JO - Br J Cancer VL - 89 UR - https://doi.org/10.1038/sj.bjc.6601400 DO - 10.1038/sj.bjc.6601400 ID - Bromwich2003 ER - TY - JOUR AU - Sakaguchi, S. AU - Yamaguchi, T. AU - Nomura, T. AU - Ono, M. PY - 2008 DA - 2008// TI - Regulatory T cells and immune tolerance JO - Cell VL - 133 UR - https://doi.org/10.1016/j.cell.2008.05.009 DO - 10.1016/j.cell.2008.05.009 ID - Sakaguchi2008 ER - TY - STD TI - Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol. 2006;24:1169–77. ID - ref8 ER - TY - JOUR AU - Boyman, O. AU - Sprent, J. PY - 2012 DA - 2012// TI - The role of interleukin-2 during homeostasis and activation of the immune system JO - Nat Rev Immunol VL - 12 ID - Boyman2012 ER - TY - JOUR AU - Liao, W. AU - Lin, J. X. AU - Leonard, W. J. PY - 2013 DA - 2013// TI - Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapy JO - Immunity VL - 38 UR - https://doi.org/10.1016/j.immuni.2013.01.004 DO - 10.1016/j.immuni.2013.01.004 ID - Liao2013 ER - TY - JOUR AU - Malek, T. R. AU - Castro, I. PY - 2013 DA - 2013// TI - Interleukin-2 receptor signaling- at the interface between tolerance and immunity JO - Immunity VL - 33 UR - https://doi.org/10.1016/j.immuni.2010.08.004 DO - 10.1016/j.immuni.2010.08.004 ID - Malek2013 ER - TY - JOUR AU - Abe, H. AU - Kamai, T. PY - 2013 DA - 2013// TI - Recent advances in the treatment of metastatic renal cell carcinoma JO - Int J Urol VL - 20 ID - Abe2013 ER - TY - STD TI - Chang CH, Qiu J, O'Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229–41. ID - ref13 ER - TY - STD TI - Ho PC, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217–28. ID - ref14 ER - TY - STD TI - Furuya N, Kamai T, Shirataki H, Yanai Y, Fukuda T, Mizuno T, et al. Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma. Cancer Immunol Immunother. 2011;60:793–808. ID - ref15 ER - TY - STD TI - Eto M, Kawano Y, Hirao Y, Mita K, Arai Y, Tsukamoto T, Hashine K, Matsubara A, Fujioka T, Kimura G, Shinohara N, Tatsugami K, Hinotsu S, Naito S, Japan RCC Trialist Collaborative Group (JRTCG) investigators. Phase II clinical trial of sorafenib plus interferon-alpha treatment for patients with metastatic renal cell carcinoma in Japan. BMC Cancer 2015;15:667. ID - ref16 ER - TY - STD TI - Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16. ID - ref17 ER - TY - STD TI - Mizuno T, Kamai T, Abe H, Sakamoto S, Kitajima K, Nishihara D, et al. Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer. BMC Cancer. 2015;15:114. ID - ref18 ER - TY - STD TI - Brivio F, Lissoni P, Fumagalli L, Rovelli F, Brivio R, Vigore’ L, Messina G, Tisi E. Correlation between soluble IL-2 receptor serum levels and regulatory T lymphocytes in patients with solid tumors. Int J Biol Markers 2008;23:121-122. ID - ref19 ER - TY - STD TI - Ma WW, Jacene H, Song D, Vilardell F, Messersmith WA, Laheru D, et al. [18F]Fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy. J Clin Oncol. 2009;27:2697–704. ID - ref20 ER - TY - JOUR AU - Linehan, W. M. AU - Rouault, T. A. PY - 2013 DA - 2013// TI - Molecular pathways: fumarate hydratase-deficient kidney cancer- targeting the Warburg effect in cancer JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-13-0304 DO - 10.1158/1078-0432.CCR-13-0304 ID - Linehan2013 ER - TY - JOUR AU - Betz, C. AU - Stracka, D. AU - Prescianotto-Baschong, C. AU - Frieden, M. AU - Demaurex, N. AU - Hall, M. PY - 2013 DA - 2013// TI - mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology JO - Proc Natl Acad Sci U S A VL - 110 UR - https://doi.org/10.1073/pnas.1302455110 DO - 10.1073/pnas.1302455110 ID - Betz2013 ER - TY - JOUR AU - Toschi, A. AU - Lee, E. AU - Gadir, N. AU - Ohh, M. AU - Foster, D. A. PY - 2008 DA - 2008// TI - Differential dependence of hypoxia-inducible factors 1 alpha and 2 alpha on mTORC1 and mTORC2 JO - J Biol Chem VL - 283 UR - https://doi.org/10.1074/jbc.C800170200 DO - 10.1074/jbc.C800170200 ID - Toschi2008 ER - TY - STD TI - Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, et al. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer. 2010;116:57–65. ID - ref24 ER - TY - STD TI - Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest. 2005;115:3623–33. ID - ref25 ER - TY - STD TI - Kaplan RN, Riba RD, Zacharoulis S, Bramley AH, Vincent L, Costa C, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature. 2005;438:820–7. ID - ref26 ER - TY - STD TI - Hiratsuka S, Nakamura K, Iwai S, Murakami M, Itoh T, Kijima H, et al. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell. 2002;2:289–300. ID - ref27 ER - TY - STD TI - Yoshida N, Oda M, Kuroda Y, Katayama Y, Okikawa Y, Masunari T, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS One. 2013;11:e78730. ID - ref28 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Nagaraj, S. PY - 2009 DA - 2009// TI - Myeloid-derived suppressor cells as regulators of the immune system JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2506 DO - 10.1038/nri2506 ID - Gabrilovich2009 ER - TY - JOUR AU - Qian, B. Z. AU - Pollard, J. W. PY - 2010 DA - 2010// TI - Macrophage diversity enhances tumor progression and metastasis JO - Cell VL - 141 UR - https://doi.org/10.1016/j.cell.2010.03.014 DO - 10.1016/j.cell.2010.03.014 ID - Qian2010 ER - TY - JOUR AU - Curran, M. A. AU - Montalvo, W. AU - Yagita, H. AU - Allison, J. P. PY - 2010 DA - 2010// TI - PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors JO - Proc Natl Acad Sci U S A VL - 107 UR - https://doi.org/10.1073/pnas.0915174107 DO - 10.1073/pnas.0915174107 ID - Curran2010 ER -